In the context of chronic diseases such as DKD, where patients experience ongoing endothelial dysfunction, the cumulative impact of long-term ROS reduction and Klotho upregulation may only become apparent after extended PTX therapy. This evidence concerns the gene KL and diabetic kidney disease.